TB Drug Shortages Put U.S. Patients in Peril, S... (ionwide shortages of the drugs as one of...)

TB Drug Shortages Put U.S. Patients in Peril, Study Finds

Date:1/18/2013

ionwide shortages of the drugs as one of the reasons for the difficulties, according to the report.

In an accompanying editorial, experts noted that since September 2011, the supply of key second-line TB drugs has been "precarious."

"Kanamycin is no longer produced in the United States, streptomycin has been intermittently unavailable because of increased international demand, and capreomycin and amikacin have been available on an intermittent basis in only small amounts because of manufacturing problems and lack of raw materials," according to the editorial.

Other causes included shipping delays (noted in 71 percent of cases), lack of resources (62 percent), and the complicated process of obtaining certain drugs (48 percent).

As a result of difficulties obtaining drugs to treat multidrug-resistant TB, 58 percent of the TB programs reported delays in treating patients, 32 percent said there were lapses or interruptions in patient treatment, and 32 percent said they were forced to use an inadequate -- and potentially less effective -- treatment regimen.

Shortages disrupt the flow of care, as well, the editorial pointed out, leading to "rationing, increased drug costs, and inefficient use of staff time." They also "increase the risk for medication errors because regimens must be adjusted, leading to confusion over drug administration schedules, adverse reactions [side effects] and [drug-to-drug] interactions," the experts wrote.

Some efforts are underway to help ease the situation. In March of 2011, the Federal Advisory Council for the Elimination of Tuberculosis created a working group to address ongoing drug shortages, and in October 2011, a presidential order directed the U.S. Food and Drug Administration and the U.S. Department of Justice to fight drug shortages occurring across the health care spectrum.

"Reliable, consistent access to second-line drugs will require the collaboration of CDC, FDA, state and local health de
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Spot Shortages of Flu Vaccine, Tamiflu Reported, FDA Head Says
2. Fentanyl Injection Shortages Reported: Severe Adverse Events as AttorneyOne Informs
3. Canada needs national approach to protect against drug shortages
4. Researchers find that simple blood test can help identify trauma patients at greatest risk of death
5. 1,800 Michigan doctors launch effort to improve health care for Medicare patients
6. Chemo Pills Effective, But Patients May Skip Doses
7. Director of the Center for Craniofacial & Dental Sleep Medicine Provides New Cutting Edge Technology for Patients Suffering with Obstructive Sleep Apnea
8. COPD patients at risk of dangerous bacterial infections
9. Physical Therapists Now Have A Powerful Adjunct To Their Therapy Plan With The New Rehab In Motion™ Program Designed For Patients Who Have Limited Or No Health Insurance
10. Obese Patients May Have Less Success With Back Surgery
11. Doctors Often Miss Signs of Problem Drinking in Patients, Study Finds

Post Your Comments:

Related Image:

TB Drug Shortages Put U.S. Patients in Peril, Study Finds

(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...

(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...

(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...

(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...

Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2

[0] Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article [0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference

... International Liver Congress 2009, the 44th annual meeting of the ... Journalist registrations are being accepted for International Liver Congress 2009, ... , Press registration is free of charge for all holders ... The official EASL press conference will be held from 13.15 ...

... A failing heart makes a lot of a hormone needed ... but not enough of the enzyme needed to activate it, ... College of Georgia researchers found people in heart failure have ... pro-atrial natriuretic peptide, a hormone made by heart muscle cells ...

... WASHINGTON, March 31 Jeffrey Levi, Ph.D., ... today before the U.S. House Energy and Commerce Committee,s ... Care Work for American Families: Protecting the Public Health." ... investing in prevention, and the importance of incorporating public ...

... March 31 The not-for-profit LENA Foundation ... Biennial Meeting of the Society of Research in Child ... Colorado, four talks and one poster will be presented ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )"This year,s SRCD is a great opportunity ...

... 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ... Award" is a most coveted, prestigious award, and ... Science and Technological Development. Submitted with the award ... preliminary trial of their Ribavirin product, confirming its ...

... March 31 Five local organizations and,individuals committed ... cholesterol,in Hispanic communities were awarded 2009 Cheerios Angel ... Chosen from a winning pool of nominations, ... healthier lifestyles and provided excellent resources to help ...

Cached Medicine News:Health News:New tests provide new insight into why patients are in heart failure 2 Health News:New tests provide new insight into why patients are in heart failure 3 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 2 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 3 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 4 Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2 Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3 Health News:Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 2 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4

International Liver Congress 2009 New tests provide new insight into why patients are in heart failure Trust for America's Health Testifies before Congress on Building Prevention into Health Reform Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S.

(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...

(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...

(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue: ... Scenario for Medical Devices in the US ... Changing Regulatory and Reimbursement ... Market Summary ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively. Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...

... Botanic Pharmaceutical Inc. (NYSE AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... recently hosted a technical exchange between 13 senior research ... and herbal medicine. China Botanic participated ...

Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.China Botanic Hosts Technical Exchange for Industry Research Experts

Sensitive Eyes drops keep soft contact lenses moist....

Lens Plus Sterile Saline Solution...

... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...

Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...

Medicine Products:

Sensitive Eyes Drops Lens Plus Sterile Saline Solution Renu MultiPlus Multi-Purpose Solution No Rub Formula Sensitive Eyes Sterile Saline Spray